Latest Research And Development News

Cann Group Limited has negotiated an extension of its NAB loan maturity and deferred upcoming interest payments, providing crucial breathing room for its capital projects and working capital needs.

Reckon Limited posted a modest revenue increase to $54.1 million for FY2024, yet net profit declined by 25.7%, reflecting margin pressures despite operational gains. The company also announced a strategic acquisition aimed at bolstering future growth.

CSL Limited reported a solid half-year performance with 5% revenue growth and a 7% rise in net profit, driven by strong demand in its Behring and Vifor segments despite challenges in Seqirus. The company reaffirmed its full-year NPATA guidance of 10-13%, signaling confidence in its operational momentum.

CSL Limited reported a solid 5% revenue increase and 6% rise in net profit after tax for the half year ended December 2024, underpinned by robust performance in its plasma therapies business despite headwinds in its influenza vaccine segment.

Queste Communications Ltd reported a robust $4.2 million net cash increase in January 2025, driven primarily by positive operating cash flows and strategic investing activities. The company’s consolidated cash position benefits from its controlling stake in Orion Equities Limited.

Nanoveu Limited has completed the strategic acquisition of Embedded A.I. Systems Pte. Ltd. (EMASS), positioning itself at the forefront of ultra-low-power AI-driven edge semiconductor solutions. This move aims to enhance its EyeFly3D™ platform and expand into rapidly growing markets such as wearables, IoT, and autonomous devices.

Neuren Pharmaceuticals has received a significant cash inflow of approximately US$50 million following the sale of a Priority Review Voucher linked to its Rett syndrome treatment. This milestone underscores the growing value of Neuren’s neurological drug portfolio and its partnership with Acadia Pharmaceuticals.

Invex Therapeutics reports a significant reduction in net loss for H1 FY2025 alongside promising pre-clinical data for Exenatide in Alzheimer’s Disease models.

Spacetalk Ltd has secured a $428,853 R&D tax rebate from the Australian Taxation Office, reinforcing its commitment to innovation while reporting a 16% increase in Annual Recurring Revenue and significant cost reductions.

Sparc Technologies has secured a fourth trial agreement with BHP Mitsubishi Alliance to test its graphene-enhanced ecosparc® coating in harsh mining conditions, aiming to validate its anti-corrosive performance against market leaders.

Audeara Limited has landed a significant US$917,000 follow-up purchase order from a global music instrument manufacturer, reinforcing the commercial viability of its hearing technology and expanding its licensing footprint.

Biome Australia has partnered with the Food and Beverage Accelerator (FaBA) to jointly develop its promising BMB18 probiotic strain, leveraging $50 million in Australian government funding while retaining full IP ownership.